Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Nobias Therapeutics Inc
Noema Pharma AG
Sumitomo Pharma Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles
DSP-3456 - Drug Profile
Product Description
Mechanism Of Action
LY-3020371 - Drug Profile
Product Description
Mechanism Of Action
History of Events
mGlu3 PAM - Drug Profile
Product Description
Mechanism Of Action
History of Events
NB-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NOE-109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pomaglumetad methionil - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBP-9881 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TS-134 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TS-161 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
VU-0650786 - Drug Profile
Product Description
Mechanism Of Action
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones
Featured News & Press Releases
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The Intertiol Congress On Schizophrenia Research
Sep 02, 2007: Investigatiol Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in ture Medicine Finds
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Camino Pharma LLC, 2022
Pipeline by Denovo Biopharma LLC, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Nobias Therapeutics Inc, 2022
Pipeline by Noema Pharma AG, 2022
Pipeline by Sumitomo Pharma Co Ltd, 2022
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022